- Adults who had atrial fibrillation (AFib) and type 1 or type 2 diabetes were less likely to notice heartbeat irregularities compared to people who had AFib without either type 1 or type 2 diabetes.
- People who have either type 1 or type 2 diabetes and AFib tended to have worse quality of life and more co-existing health conditions compared to those who have AFib alone.
Embargoed until 4 a.m. CT/5 a.m. ET Wednesday, Nov. 10, 2021
(NewMediaWire) – November 10, 2021 – DALLAS – Adults with type 1 or type 2 diabetes and atrial fibrillation were less likely to notice symptoms of irregular heartbeat, more likely to have a lower quality of life and experienced more coexisting health conditions than people with atrial fibrillation who did not have type 1 or type 2 diabetes, according to new research published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.
At least 2.7 million Americans live with atrial fibrillation, often called AFib, which is an irregular heartbeat or arrythmia that can lead to blood clots, stroke, heart failure and other heart-related complications. By 2030, the number of people in the U.S. with AFib is expected to climb to an estimated 12.1 million. Chronic health conditions including type 1 or type 2 diabetes, asthma and hyperthyroidism are known to increase the risk of AFib.
“Since diabetes is one of the major risk factors for AFib, our team investigated whether patients with and without diabetes differ in terms of atrial fibrillation symptoms and complications,” said study author Tobias Reichlin, M.D., professor of cardiology at Bern University Hospital at the University of Bern in Bern, Switzerland. “This research can provide insights on improving the management of atrial fibrillation and prevention of its complications.”
Researchers studied 2,411 patients diagnosed with atrial fibrillation who were enrolled at 14 health care centers in Switzerland from 2014 to 2017 as part of the Swiss-AF (Swiss Atrial Fibrillation) Study. The average age of the study’s participants was approximately 74 years, and about 27% were women.
Upon enrollment in the study, participants were required to receive a clinical examination, blood sampling, cognitive assessment, quality of life assessment and 5-minute resting ECG (electrocardiogram). About 17% of the study participants were diagnosed with diabetes, according to their medical records and if they were taking any diabetes medications; they were not classified by the U.S. standards of type 1 or type 2 diabetes. Among the study participants diagnosed with diabetes, they were further categorized as having either insulin-dependent diabetes or non-insulin dependent diabetes, both of which included people with type 1 and type 2 diabetes as defined in the U.S.
To determine how diabetes may affect AFib patients, researchers compared AFib symptoms, quality of life outcomes, cardiac comorbidities and neurological comorbidities among participants with and without diabetes. Compared to people with AFib who did not have diabetes:
- People with diabetes were about 25% less likely than those without diabetes to recognize common symptoms of atrial fibrillation such as a rapid heartbeat;
- People with diabetes were three times more likely than those without diabetes to have high blood pressure; 55% more likely to have had heart attacks; and about twice as likely to have heart failure; and
- People with diabetes had a 39% increased stroke risk and were 75% more likely to have cognitive impairment.
“It is remarkable to find that patients with diabetes had a reduced recognition of atrial fibrillation symptoms,” Reichlin said. “The reduced perception of atrial fibrillation symptoms may result in a delayed diagnosis of atrial fibrillation, and, consequently, more complications such as stroke. Our findings raise the question of whether patients with diabetes should be routinely screened for atrial fibrillation.”
When researchers examined specific areas related to quality of life, they also found that having diabetes and AFib negatively impacted mobility, self-care and normal activities more so than for the people without diabetes.
”These important new findings from the large Swiss AF study show compared to AFib patients without diabetes, those with diabetes were less likely to experience any symptom related to atrial fibrillation,” said Prakash Deedwania, M.D., a member of the scientific advisory board for Know Diabetes By Heart (KDBH), a joint initiative of the American Heart Association and the American Diabetes Association, the immediate past chair of the American Heart Association Diabetes Committee and a professor of medicine at the University of California, San Francisco School of Medicine. “These results were seen even though people with diabetes and AFib had more coexisting health conditions such as high blood pressure, as well as a history of heart attack and heart failure. Keeping these new observations in mind, along with the serious consequences of failing to recognize AFib in time, it seems prudent to consider screening older patients with diabetes for AFib so that treatment may be initiated when appropriate.”
The researchers note several potential limitations to this research. The diagnosis of diabetes was based on the medical history of the study’s participants rather than laboratory criteria; therefore, the prevalence of diabetes may have been underreported. Also, data was not available on the duration of diabetes or the degree of glycemic control. Additionally, the study included only residents of Switzerland, therefore, the generalizability of the findings to other populations or people living in other countries requires further investigation. Future studies among larger, more diverse populations of people are needed to confirm these findings.
Co-authors are Arjola Bano, M.D., Ph.D.; Nicolas Rodondi, M.D., M.A.S.; Jürg H. Beer, M.D.; Giorgio Moschovitis, M.D.; Richard Kobza, M.D.; Stefanie Aeschbacher, Ph.D.; Oliver Baretella, M.D., Ph.D.; Taulant Muka, M.D., Ph.D.; Christoph Stettler, M.D.; Oscar H. Franco, M.D., Ph.D.; Giulio Conte, M.D., Ph.D.; Christian Sticherling, M.D.; Christine S. Zuern, M.D.; David Conen, M.D., M.P.H.; Michael Kühne, M.D.; Stefan Osswald, M.D.; and Laurent Roten, M.D. Authors’ disclosures are listed in the manuscript.
The study was funded by the Swiss National Science Foundation, the Swiss Heart Foundation, the Foundation for Cardiovascular Research Basel and the University of Basel.
Statements and conclusions of studies published in the American Heart Association’s scientific journals are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173